EffRx Pharmaceuticals Signs Exclusive License Agreement with Dipharma SA and Launches Miglustat Dipharma in Switzerland

FREIENBACH, Switzerland – EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced it has recently entered into an exclusive license agreement with Dipharma SA, a Swiss specialty pharmaceutical company, developing high quality, improved medicines for rare diseases. Under the terms of the agreement, EffRx has received

Learn More

EffRx Pharmaceuticals Signs Exclusive License Agreement with Diurnal for the Registration and Commercialization of Alkindi® and Submits Market Authorization Application in Switzerland

FREIENBACH, Switzerland (BUSINESS WIRE)-– EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced it has recently entered into an exclusive license agreement with Diurnal Group plc, a specialty pharmaceutical company targeting patient needs in chronic endocrine diseases, for the registration and commercialization of Alkindi® for pediatric adrenocortical

Learn More

World Osteoporosis Day – WOD marked on October 20th: THAT’S OSTEOPOROSIS

Countdown to World Osteoporosis Day: A digital countdown checklist is an easy way to learn good bone health basics. Get Started Now! WOD, marked on October 20 each year, is a year-long campaign dedicated to raising global awareness of the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal diseases. It aims to put bone

Learn More

EffRx Mourns Passing of Board Member Anders Wiklund

FREIENBACH, Switzerland, 19th August 2020. The leadership of EffRx Pharmaceuticals SA is extremely saddened to announce the passing of longtime Board Member and former Chairman, Anders P. Wiklund. Anders, a Swedish citizen, has been a board member of EffRx since its incorporation in Switzerland in 2009, and served as Chairman of EffRx between 2015 and

Learn More

EffRx to Showcase Binosto® at the Virtual WCO-IOF-ESCEO 2020 Congress

EffRx Pharmaceuticals SA is proud to announce that it will participate in the 20th Edition of the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, starting on the 20th of August 2020. The WCO-IOF-ESCEO Congress is the world’s leading clinical conference on bone, joint and muscle health and therefore the ideal venue for EffRx to

Learn More

EffRx Pharmaceuticals Statement on COVID-19

The globe has literally gone into quarantine due to the COVID-19 outbreak. This is an unprecedented crisis situation in terms of breadth and scale, from a global health, social and economic standpoint. While committed to keep our core activities unaffected, EffRx has implemented measures aimed at guaranteeing business operation continuity, with particular focus on the

Learn More

Meet the EffRx Team at the 25th Annual BIO-Europe International Conference from November 11-13, 2019 in Hamburg

EffRx will be attending Europe’s largest life science partnering conference, BIO-Europe, which offers countless opportunities to engage with global life science partners. This year´s BIO-Europe partnering event will again draw over 4,000 industry attendees from over 60 countries, representing more than 2,000 companies for three days of high-level networking. To set up a meeting, please

Learn More

EffRx Pharmaceuticals | EffRx